Tenecteplase or Alteplase for Stroke: How to Read the Noninferiority Trials

The short answer

In January 2026, the American Heart Association and American Stroke Association issued a new guideline giving a Class I recommendation to treat eligible patients with acute ischemic stroke using either tenecteplase or alteplase within 4.5 hours of symptom onset. That endorsement of two interchangeable clot-busting drugs rests almost entirely on noninferiority trials, a study design built to ask whether a new option is "not meaningfully worse" than an established one rather than whether it is better. Reading those trials well means checking three things: the prespecified margin, the analysis population, and what the confidence interval actually rules out. This article is educational and not medical advice.

Why the question was framed as noninferiority, not superiority

Alteplase has been the standard thrombolytic for ischemic stroke since the mid-1990s. When a treatment already works and is entrenched, the practical question for a challenger is rarely whether it is dramatically better. Tenecteplase is a bioengineered variant of the same parent molecule with a longer half-life, which allows it to be given as a single intravenous bolus instead of the roughly 60-minute infusion alteplase requires. That logistical difference matters in a stroke bay, where minutes translate into salvaged brain tissue and where a bolus is easier to give before transfer between hospitals.

So the trials were not designed to prove tenecteplase heals more brains. They were designed to show it does not do enough worse to matter, while offering operational advantages. That is the logic of a noninferiority trial, and it changes how the numbers should be read.

The margin is the whole argument

Every noninferiority trial declares, before enrollment, how much worse the new treatment is allowed to be and still count as acceptable. This is the noninferiority margin. If the drugs turn out identical, the margin never comes into play. But the margin is where the intellectual honesty of the design lives, because a generous margin makes it easier to declare success on thinner evidence.

The AcT trial in Canada, published in The Lancet in 2022, illustrates this cleanly. Its primary outcome was the proportion of patients reaching a modified Rankin Scale score of 0 to 1 at 90 to 120 days, meaning little or no residual disability. Noninferiority was declared if the lower bound of the 95% confidence interval for the difference between tenecteplase and alteplase stayed above negative 5 percentage points. In the result, 36.9% of the tenecteplase group and 34.8% of the alteplase group reached that excellent outcome, a difference of about 2 percentage points with a confidence interval running from roughly negative 2.6 to positive 6.9. Because the lower edge of that interval sat above the negative 5 threshold, noninferiority was met.

Notice what that does and does not say. It does not say the drugs are identical. It says the data are compatible with tenecteplase being as much as about 2.6 points worse, or nearly 7 points better, and the trial ruled out the possibility that it is more than 5 points worse. Whether 5 points is a clinically tolerable loss is a judgment made by the trialists in advance, and a reader is entitled to interrogate it.

Different trials, different margins, same direction

The 2026 guideline does not rest on one study. TRACE-2, published in The Lancet in 2023, enrolled patients across centers in China who were eligible for standard thrombolysis but not for clot retrieval. It expressed its margin as a ratio rather than a difference, requiring the lower bound of the risk ratio to stay above 0.937. At 90 days, 62% of the tenecteplase group and 58% of the alteplase group reached a modified Rankin Scale of 0 to 1, and the result cleared that ratio-based threshold. ATTEST-2 in the United Kingdom added further data within the same window.

When several trials using somewhat different margins, populations, and statistical framings all land on the same side of their respective thresholds, the collective signal strengthens. A published meta-analysis pooling NOR-TEST, AcT, and TRACE-2 reported excellent outcomes in 53.0% of tenecteplase patients versus 50.5% of alteplase patients, a small absolute difference that met its prespecified noninferiority threshold with no detectable heterogeneity across the studies. Consistency across designs is more persuasive than any single trial, because it makes an idiosyncratic margin or a fluke population less likely to explain the result.

Three questions worth asking of any noninferiority trial

First, was the analysis population the conservative one. In superiority trials, intention-to-treat analysis is the rigorous default because it preserves randomization. In noninferiority trials, intention-to-treat can paradoxically be less conservative, because dropout and crossover tend to blur differences and make two treatments look more alike. Careful noninferiority trials report both intention-to-treat and per-protocol analyses and expect them to agree.

Second, does the confidence interval exclude a difference you would care about, not merely exclude zero. A result can be statistically noninferior while its confidence interval still touches a loss that a patient might find meaningful. The reader's job is to look at that lower bound and decide whether the worst case it permits is acceptable.

Third, is the comparator itself still a fair benchmark. Noninferiority to an established drug is only reassuring if that drug genuinely works in the population studied. Here alteplase has a deep evidence base within 4.5 hours, so the anchor is sound.

What the design does and does not license

The clean way to state the conclusion is that these trials support treating the two drugs as reasonable alternatives within the 4.5-hour window, with tenecteplase carrying the practical advantage of single-bolus administration. That is the posture the 2026 guideline takes when it endorses either agent. What the noninferiority framework does not license is the stronger claim that the drugs are proven equal, or that tenecteplase is proven superior on outcomes. Those are different questions that these trials were not built to answer, and reading the design carefully is what keeps the two claims apart.